文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

抗炎治疗与危重症患者贫血延迟出现及输血需求减少相关:两项研究结果

Anti-inflammatory therapies are associated with delayed onset of anemia and reduction in transfusion requirements in critically ill patients: results from two studies.
PubMed 文献 · Crit Care · 2024-04-09
一句话结论在COVID-19所致低氧性呼吸衰竭的危重症患者中,使用类固醇或类固醇联合IL-6阻断剂与血红蛋白下降更慢、输血更少相关。

该研究分析了两个队列:观察性队列(n=772)和REMAP-CAP验证队列(n=119),均为COVID-19所致低氧性呼吸衰竭的危重症患者,分为未治疗组、类固醇组和类固醇联合IL-6阻断剂组。结果显示,两个队列中治疗组各时间点血红蛋白水平均高于未治疗组;观察性队列中联合治疗组的输血发生率及输血人数均低于未治疗组。多因素分析控制基线Hb不平衡和机械通气后,类固醇使用仍与Hb下降更慢相关,联合治疗仍与Hb下降更慢及输血更少相关,验证队列结果一致。结论提示免疫调节治疗与Hb下降更慢及输血更少相关,炎症可能是危重症贫血的重要原因。

要点

  • 在COVID-19低氧性呼吸衰竭危重症患者中,类固醇或类固醇联合IL-6阻断剂组各时间点血红蛋白水平均高于未治疗组。
  • 观察性队列中,联合治疗组输血发生率和输血人数均低于未治疗组。
  • 多因素分析控制基线Hb不平衡和机械通气后,类固醇使用仍与Hb下降更慢相关,联合治疗仍与Hb下降更慢及输血更少相关。
  • 验证队列(REMAP-CAP子集,n=119)结果与观察性队列一致。
  • 作者认为炎症可能是危重症贫血发生的重要原因。

适用人群与场景

  • COVID-19所致低氧性呼吸衰竭的危重症患者,来自观察性队列(n=772)和REMAP-CAP验证队列子集(n=119)。
  • 患者分为未治疗组、类固醇组和类固醇联合IL-6阻断剂组。

处置流程与药物剂量

  • 原文提及的治疗分组为:未治疗、类固醇、类固醇联合IL-6阻断剂;具体药物剂量、给药途径和疗程原文未写明。

研究设计与关键结果

  • 研究类型:观察性队列(n=772)加REMAP-CAP验证队列子集(n=119),人群为COVID-19所致低氧性呼吸衰竭的危重症患者。
  • 两个队列中,治疗组各时间点血红蛋白水平均高于未治疗组。
  • 观察性队列中,联合治疗组输血发生率和输血人数均低于未治疗组。
  • 多因素分析控制基线Hb不平衡和机械通气后,类固醇使用仍与Hb下降更慢相关,联合治疗仍与Hb下降更慢及输血更少相关。
  • 验证队列结果与观察性队列一致。

证据类型、等级与局限

  • 证据类型:观察性队列研究加验证队列分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为免疫调节治疗与危重症COVID-19患者Hb下降更慢及输血更少相关,提示炎症可能是危重症贫血的重要原因。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Anemia is a hallmark of critical illness, which is largely inflammatory driven. We hypothesized that the use of anti-inflammatory agents limits the development of anemia and reduces the need for red blood cell (RBC) transfusions in patients with a hyper-inflammatory condition due to COVID-19.

METHODS: An observational cohort (n = 772) and a validation cohort (a subset of REMAP-CAP, n = 119) of critically ill patients with hypoxemic respiratory failure due to COVID-19 were analyzed, who either received no treatment, received steroids or received steroids plus IL-6 blocking agents. The trajectory of hemoglobin (Hb) decline and the need for RBC transfusions were compared using descriptive statistics as well as multivariate modeling.

RESULTS: In both cohorts, Hb level was higher in the treated groups compared to the untreated group at all time points. In the observational cohort, incidence and number of transfused patients were lower in the group receiving the combination treatment compared to the untreated groups. In a multivariate analysis controlling for baseline Hb imbalance and mechanical ventilation, receipt of steroids remained associated with a slower decline in Hb level and the combination treatment remained associated with a slower decline of Hb and with less transfusions. Results remained the same in the validation cohort.

CONCLUSION: Immunomodulatory treatment was associated with a slower decline in Hb level in critically ill patients with COVID-19 and with less transfusion. Findings point toward inflammation as an important cause for the occurrence of anemia in the critically ill.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Bolscher M, Koster SCE, Koopmans M, et al. Anti-inflammatory therapies are associated with delayed onset of anemia and reduction in transfusion requirements in critically ill patients: results from two studies. Crit Care. 2024. PMID: 38594746. doi:10.1186/s13054-024-04898-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。